Histological Subtypes Drive Distinct Prognostic Immune Signatures in Classical Hodgkin Lymphoma.
Fiche publication
Date publication
octobre 2022
Journal
Cancers
Auteurs
Membres identifiés du Cancéropôle Est :
Dr ROSSI Cédric
Tous les auteurs :
Lamaison C, Ferrant J, Gravelle P, Traverse-Glehen A, Ghesquières H, Tosolini M, Rossi C, Ysebaert L, Brousset P, Laurent C, Syrykh C
Lien Pubmed
Résumé
Despite the success of standard front-line chemotherapy, 20% of classical Hodgkin lymphoma (cHL) patients still relapse or have refractory disease (r/r), and a subset of them die due to disease progression. There is a critical lack of predictive factors for early identification of those r/r patients who may benefit from new therapeutic strategies. This study aimed to evaluate the dynamic expression of 586 immune-related genes in a cohort of 42 cHL patients including 30 r/r cHL after first-line chemotherapy. Gene expression profiling (GEP) using NanoString technology identified a 19-gene immune signature at diagnosis predictive of cHL relapse, but dependent on histological subtypes. Genes related to tumor survival were found upregulated while genes related to B-lineage were downregulated at diagnosis in r/r nodular sclerosis cHL. In contrast to the mixed-cellularity subtype, comparative GEP analyses between paired diagnosis/relapse biopsies of nodular sclerosis cHL showed 118 differentially expressed genes, supporting an immune contexture switch at relapse with upregulation of immunosuppressive cytokines, such as and , and downregulation of the T-cell co-stimulatory receptor . These results indicate that the predictive value of immune signature in cHL is strongly influenced by histological subtype which should be considered when assessing new immunotherapy target strategies.
Mots clés
Hodgkin lymphoma, gene expression profiling, histological subtypes, immune prognosis signature
Référence
Cancers (Basel). 2022 10 6;14(19):